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Many individuals infected with HIV eventually present 
with evidence of neurological involvement, including 
cognitive deterioration. Autopsy studies of patients 
with HIV-associated dementia (HAD) demonstrate 
damage to the deep white matter areas involved in 
sub-cortical dementia (including the caudate nucleus 
and basal ganglia).8 This finding is complemented by 
results of both computed tomography (CT) and struc-
tural magnetic resonance imaging (sMRI), with asso-
ciation between HAD and both diffuse atrophy with 
ventricular dilatation9 and deep white matter lesions. 
Furthermore, a correlation between declining cognitive 
function and the loss of volume in certain brain struc-
tures, including the basal ganglia and caudate nucleus, 
has also been reported.10
Dynamic contrast-enhanced MRI has identified sub-
cortical grey and frontal white matter as the principal 
sites of early metabolic abnormalities in HIV disease.11 
Both increased regional cerebral blood volume and 
post-contrast enhancement have been reported in the 
basal ganglia in moderate and advanced HAD, reflect-
ing increased vascularity and blood-brain barrier (BBB) 
permeability. These findings are consistent with the 
characteristics of the early neurological deficits, and 
the known predilection of HIV for the basal ganglia.12 
The degree of neurocognitive impairment in HIV is cor-
related both with the degree of BBB breakdown in the 
basal ganglia and with viral load.13 
Diffusion tensor imaging (DTI), a recent advance in MRI 
methods, is uniquely suited to the study of subtle white 
matter abnormalities that are not detected by tradi-
tional MRI. DTI can be used to quantify the magnitude 
and directionality of tissue water mobility (i.e. self-dif-
fusion). Barriers such as myelin sheaths, membranes, 
or white matter tracts result in greater self-diffusion 
along the axis of the barrier and reduced diffusion 
out of the tract. This type of restricted self-diffusion 
is termed ‘anisotropic’. Fractional anisotropy (FA) is a 
measure derived from the diffusion tensor imaging 
that assesses the degree of anisotropic self-diffusion, 
i.e. the integrity of the white matter tract.14 The higher 
the FA the healthier the tract; lower FA indicates dam-
age to its integrity. DTI provides us with information 
about the large-scale networks that are made up of 
long tracts connecting distant relay stations in the 
brain (Fig. 1).15 These networks are important for the 
development of higher brain functions such as lan-
guage, praxis, social behaviour and emotion. Lesions 
affecting white matter connections lead to dysfunc-
tion, and cognitive disorders are sometimes better ex-
plained by a disconnection mechanism between dis-
tant cerebral regions than by primary damage of those 
regions themselves.16
DTI studies have revealed central nervous system ab-
normalities in asymptomatic HIV-positive patients 
with no cognitive impairment and normal structural 
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Advanced HIV disease is strongly associated with an increased occurrence of various neuropsychiatric disorders,1 
and highly active antiretroviral therapy (HAART) is an important aspect of managing these conditions effec-
tively.2 In addition, there is growing recognition that many HIV-infected individuals will develop neuropsychiat-
ric disorders relatively early in the course of HIV disease, in many cases before CD4 cell counts drop below 500 
cells/µl.3 However, it is not known who in the earlier phases of the disease will go on to develop neurocognitive 
disorders, or who will respond to treatment.4,5 New approaches in neuro-imaging have the potential to detect 
early HIV-associated damage in the brain. Preliminary evidence suggests that the neurotoxic effects of HIV re-
sult in damage to white matter tracts in the brain.6 Once damage is established and related cognitive disorders 
ensue, the ability of HAART to reverse existing dysfunction is probably limited.7 Earlier treatment with HAART 
in at-risk or minimally symptomatic patients may prevent further decline in cognition and delay the course of 
HIV disease. 
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MR studies. Diffuse damage to cerebral white matter, 
as evidenced by pallor on DTI, is one of the most fre-
quent neuropathological features of HIV-1 infection 
and has been found to be particularly prominent in the 
advanced stages of the disease.17 The white matter pal-
lor has been found to be more prevalent and severe in 
patients with HAD.17 
DTI abnormalities have been reported in the frontal 
white matter of cognitively asymptomatic patients in-
fected with HIV,18 and MR spectroscopy studies indi-
cate that this region may be subject to early injury in 
patients infected with HIV.19 
Studies utilising DTI have identified sub-cortical white 
matter and corpus callosum abnormalities in patients 
with HIV, despite normal-appearing white matter on 
MR and non-focal neurological examinations20 (Fig. 2). 
Patients with the largest anisotropy decreases had the 
most advanced HIV disease. Interestingly, patients with 
the lowest viral loads and normal anisotropy were re-
ceiving HAART. This has led some to suggest that DTI 
Fig. 1. DTI tractography showing axial, sagittal and coronal views in an individual patient. Areas shaded green represent white 
matter tracts from anterior to posterior, those in blue inferior to superior, those in red, from left to right. It is possible to isolate 
regions of interest, or to detect areas where significant abnormalities in integrity of white matter occur.
Fig. 2. DTI images showing changes in FA in three groups of patients by clinical severity. These changes reflect significant 
differences between the groups compared with HIV-negative controls, and indicate (i) that FA is impaired across the spectrum 
of HIV-associated neurocognitive disorder, including asymptomatic neuropsychological impairment, and (ii) that different 
regions may be affected across different severities, with some affected areas being responsible for a greater degree of clinical 
impairment. The amount of FA does not correspond to the location or severity of FA.
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could be used as a potential biomarker of brain injury 
in patients infected with HIV.21
DTI and other emerging neuro-imaging technologies 
may provide markers for early CNS disease in HIV-posi-
tive patients, allowing for the earliest possible detec-
tion of cognitive impairment. This in turn may facili-
tate early preventive antiretroviral treatment to reduce 
long-term damage. Novel imaging techniques such as 
DTI applied in individuals with mild forms of neuro-
cognitive disorder may be a good place to start. Stud-
ies examining response to HAART in patients infected 
with HIV will be important to determine whether DTI 
abnormalities reflect reversible or more advanced, ir-
reversible injury. Correlates of white matter damage 
and neurocognitive decline need to be sought, includ-
ing whether measures of white matter damage in the 
central nervous system correlate with viral load, illness 
duration, age, treatment exposure and treatment ad-
herence. These factors are almost certainly critical in 
determining the overall impact of HIV on brain func-
tion, and in particular on white matter integrity. 
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